Sorrento Announces Selection of T-VIVA-19™ as Targeted Protein Vaccine Candidate for SARS-CoV-2

NEXT STORY
Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case
PREV STORY
Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AstraZeneca completes agreement with LEO Pharma

This announcement contains inside information 16 August 2016 07:00 ASTRAZENECA COMPLETES GLOBAL LICENCING AGREEMENT ...

author_avatar
NASDAQ Market News

Delcath Systems to Present at Upcoming Virtual Investor Conferences

author_avatar
NASDAQ Market News

Veterinary Practice Management Software Market Worth $539.7 Million By 2028 – Exclusive Report by Meticulous Research®

author_avatar
NASDAQ Market News